Vosevi is a fixed-dose combination tablet that contains sofosbuvir, velpatasvir, and voxilaprevir, and is approved for the treatment of chronic hepatitis C virus (HCV) genotypes 1-6 in adult patients without cirrhosis or with mild cirrhosis.
It is the first therapy approved for patients who have been previously treated with sofosbuvir or other direct acting antiviral HCV drugs that inhibit NS5A.
Overall, 96% to 97% of patients in trials who received Vosevi had no virus detected in the blood 12 weeks after.
Adverse reactions include: headache, fatigue, diarrhea, and nausea.
Patients taking rifampin should not receive this drug.
Hepatitis B reaction (HBV) has been reported among patients with HCV/HBV coinfection who are not taking antiviral therapy for HBV.